Global mTOR (Mammalian Target of Rapamycin) Inhibitors Market 2019-2023: Introduction of Novel Drug Delivery Systems and Combination Therapies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 28, 2019--
The “Global mTOR (Mammalian target of rapamycin) Inhibitors Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The mTOR inhibitors market will register a CAGR of over 3% by 2023.
The strong prevalence of oncology indications is one of the key factors expected to trigger market growth during the forecast period. Vendors are conducting studies on target specific drugs to meet the gap between the demand and supply of these therapies. Factors including the increasing geriatric population and changes in lifestyle have also contributed to the oncology indications, in turn, contributing to the mTOR Inhibitors market growth during the forecast period.
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market segmentation analysis
PART 04: MARKET SIZING
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
PART 06: MARKET SEGMENTATION BY ROA
Market segmentation by RoA
Comparison by RoA
Oral therapy - Market size and forecast 2018-2023
Intravenous therapy - Market size and forecast 2018-2023
Market opportunity by RoA
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
Market positioning of vendors
- Biocon Ltd.
- Intas Pharmaceuticals Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/r/f5bma2
View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005669/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/28/2019 01:23 PM/DISC: 05/28/2019 01:23 PM